RFA-HG-22-019: Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers (U01 Clinical trials not allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $350,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 1, 2022.
From the official notice on Grants.gov, last changed August 11, 2022. Checked November 7, 2026.
- Award ceiling$350,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNHGRI
- Median yearly award$549,878
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-HG-22-019 were run by National Human Genome Research Institute (NHGRI, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HG-22-019 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-HG-21-030 | August 6, 2021 | Closed November 1, 2021 | Closed |
Key dates
| Posted | August 11, 2022 |
|---|---|
| Deadline | November 1, 2022 |
| Archived by Grants.gov | December 7, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $549,878; it allows up to $350,000 per award.
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Data Analysis and Validation (DAV) Centers to join the new NHGRI program called "Molecular Phenotypes of Null Alleles in Cells (MorPhiC)". The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase 1 will also assess the scale limitations of such methods, develop common data formats, establish use cases for this catalog, and inform whether and how a potential second phase will be implemented. The DAV Centers will develop computational models and data analysis and visualization methods to evaluate and help ensure the utility of the MorPhiC data.
Funded under RFA-HG-22-019 so far
NIH funded 3 projects under RFA-HG-22-019 in fiscal 2023 to 2026, at 3 institutions. The median yearly award was $549,878.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| MorPhiC: Constructing a Catalog of Cellular Programs to Identify and Annotate Human Disease Genes | Stanford University | 2026 | $470,265 |
| Statistical Methods for Inferring Gene-Phenotype Associations Using Omic Data from Gene Knockout and Human Phenotype Studies | Fred Hutchinson Cancer Center | 2026 | $551,382 |
| Multi-omic phenotyping of human transcriptional regulators | Jackson Laboratory | 2026 | $545,877 |
Who has won Human Genome Research grants before
From fiscal 2021 to 2025, Human Genome Research (93.172) awarded $2.2 billion across 1,255 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 59 | $153 million |
| University of Washington | Washington | 46 | $123 million |
| The Broad Institute, Inc | Massachusetts | 22 | $119 million |
| University of California Santa Cruz | California | 17 | $64.7 million |
| Baylor College of Medicine | Texas | 24 | $62.9 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HG-22-019 still open?
No. It closed on November 1, 2022.
Who can apply for Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers (U01 Clinical trials not allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers (U01 Clinical trials not allowed)?
Closed November 1, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $350,000 each.
Who has been funded under RFA-HG-22-019?
NIH RePORTER lists 3 projects funded under RFA-HG-22-019 in fiscal 2023 to 2026, at 3 institutions. The most were at Stanford University, Fred Hutchinson Cancer Center, Jackson Laboratory.
Who has won Human Genome Research grants before?
The largest recipients over five fiscal years were The Leland Stanford Junior University, University of Washington, The Broad Institute, Inc. The program made 1,255 awards worth $2.2 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)